Global lung cancer diagnostics market $3 billion by 2024

JOIN NOW

Free Project Sample – This is an ongoing global program. Please review our research program before making a purchase decision. We provide free access to qualified executives who drive the strategy, business development, sales & marketing and product management functions at recommended companies. Previews provide in-depth insider access to business trends; competing brands; domain expert profiles; and market data templates and much more. You can also create your own custom report using our MarketGlass Platform that offers thousands of data bytes without the obligation to purchase our report. Example of registry

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

ABSTRACT-

Reaching Global Lung Cancer Diagnostics Market $3 billion by 2024
Lung cancer is the leading cause of cancer death worldwide. The disease is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 80-85% of cases. Early detection of lung cancer, both for NSCLC and SCLC, is becoming an increasing priority worldwide, which in turn drives the demand for lung cancer diagnostics. Amid the COVID-19 crisis, the global lung cancer diagnostics market is expected to reach US$3 billion by 2024, with a compound annual growth rate (CAGR) of 8.0% over the analysis period. United States represents the largest regional market for Lung Cancer Diagnostics, accounting for an estimated 27.0% share of the global total. The market is expected to reach: US$803.9 million at the end of the analysis period. China is expected to lead the growth and emerge as the fastest growing regional market with a CAGR of 11.3% over the analysis period.

The market is driven by an increasing incidence of lung cancer, increasing awareness of the symptoms and severity of the condition, technological advances and the launch of new products. More focus on the development of lung cancer-specific biomarkers bodes well for market growth. The ability of such diagnostic tools to enable personalized treatment of lung malignancies is driving market growth. The rapid increase in the number of smokers in developing regions is also an important growth driver for the lung cancer diagnostics market. Significant advances in diagnosis and early detection are changing the landscape of lung cancer treatment. The high prevalence of non-small cell lung cancer (NSCLC) is particularly driving interest in the diagnostic value of liquid biopsies. The US has the largest market share, thanks to key factors such as growing patient awareness, high market penetration of innovative and technologically advanced products, and rapid urbanization and industrial development. The increasing prevalence of lung cancer in the region, caused by an increase in risk factors such as cigarette smoking, exposure to secondhand smoke, occupational exposure to cancer-causing chemicals, has stimulated the development of innovative and advanced diagnostic solutions. Grow in Asia-Pacific The region is fueled by key growth drivers, such as an increasing awareness of lung cancer symptoms, an emerging demand for advanced lung cancer diagnostic tools, improvement of healthcare infrastructure and a large population of patients with unmet clinical needs. Rising healthcare expenditure and the presence of a large patient pool in countries such as India and China is expected to offer significant growth opportunities.

The molecular testing market is expected to grow most rapidly during the analysis period. Molecular tests are generally done on tissue from a biopsy or surgery, as well as on blood taken from a vein. The rapid pace of advances and innovations in molecular diagnostic technology is leading to the development and launch of several new types of diagnostic testing techniques, which aid the use of molecular testing for the diagnosis of lung cancer. The use of molecular tests to diagnose lung cancer also facilitates the development of personalized treatments. A continued increase in investment in R&D initiatives to develop biomarker-based molecular tests for the detection of lung cancer will also support the growth of the segment. Lake

MarketGlass Platform
Our MarketGlass Platform is a free full-stack knowledge center that can be custom configured for the intelligence needs of today’s busy business executive! This influencer-driven interactive research platform is at the heart of our primary research activities, drawing on unique perspectives from participating executives around the world. Features include – enterprise-wide peer-to-peer collaborations; previews of research programs relevant to your business; 3.4 million domain expert profiles; competing company profiles; interactive research modules; generate custom reports; follow market trends; competing brands; create and publish blogs and podcasts using our primary and secondary content; worldwide domain event tracking; and much more. Client companies have full insider access to the project data stacks. Currently used by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and can be accessed through our website www.StrategyR.com or via our just released mobile application at iOS or android

About Global Industry Analysts, Inc. & StrategyR
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher, the world’s only influencer-driven market research firm. GIA proudly serves more than 42,000 customers from 36 countries and has been known for accurate forecasts of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
E-mail: [email protected]

LEFT
Join our expert panel
https://www.strategyr.com/Panelist.asp

Connect with us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

follow us on twitter
https://twitter.com/marketbytes

Journalists and media
[email protected]

SOURCE Global Industry Analysts, Inc.

rt

Related Links

http://www.strategyr.com